Browse MMP19

Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00045 Hemopexin
PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

Endopeptidase that degrades various components of the extracellular matrix, such as aggrecan and cartilage oligomeric matrix protein (comp), during development, haemostasis and pathological conditions (arthritic disease). May also play a role in neovascularization or angiogenesis. Hydrolyzes collagen type IV, laminin, nidogen, nascin-C isoform, fibronectin, and type I gelatin.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001541 ovarian follicle development
GO:0001542 ovulation from ovarian follicle
GO:0001554 luteolysis
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0014074 response to purine-containing compound
GO:0022602 ovulation cycle process
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0030728 ovulation
GO:0032963 collagen metabolic process
GO:0042698 ovulation cycle
GO:0043062 extracellular structure organization
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045137 development of primary sexual characteristics
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0046683 response to organophosphorus
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0048608 reproductive structure development
GO:0051591 response to cAMP
GO:0061458 reproductive system development
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1442490: Collagen degradation
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP19 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP19 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6470.0175
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9850.378
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.390.586
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2130.0922
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.030.323
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1740.949
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3970.301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0990.937
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7270.594
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8610.432
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9010.191
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4580.0132
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP19. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP19. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP19.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP19. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP19 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP19 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP19
Namematrix metallopeptidase 19
Aliases RASI-1; MMP18; matrix metalloproteinase 19; CODA; matrix metalloproteinase RASI; matrix metalloproteinase-18 ......
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP19 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP19.
ID Name Drug Type Targets #Targets
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23